GlassScriptPhysician profile
Pierre C Deltor
NPI 1730138710
$4,049.15
in general payments reported to CMS, 2019-2025
37 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $338 · 2021: $302 · 2022: $673 · 2023: $809 · 2024: $464 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,789 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,789.10 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $603.45 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $509.90 | 2019-2025 | Airsupra |
| Novo Nordisk INC | $431.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $294.31 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $263.33 | 2019-2025 | Biktarvy |
| Janssen Pharmaceuticals, INC | $216.09 | 2019-2022 | |
| Mylan Specialty L.P. | $156.17 | 2023 | Yupelri |
| Abiomed | $146.36 | 2023 | Impella |
| Pfizer INC. | $144.47 | 2019-2025 | |
| Atricure, INC. | $135.56 | 2022 | |
| Boston Scientific Corporation | $114.14 | 2019-2021 | |
| Amgen INC. | $97.80 | 2024-2025 | Repatha, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $77.07 | 2019-2022 | |
| Nevro Corp. | $72.20 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.27 | 2019-2023 | Xifaxan |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $60.52 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $59.27 | 2024-2025 | Eliquis |
| Exact Sciences Corporation | $58.34 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $53.44 | 2022-2025 | Jardiance |
| Allergan, INC. | $52.27 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $43.79 | 2022 | |
| Dexcom, INC. | $43.06 | 2024-2025 | Dexcom G6 Transmitter |
| Biosense Webster, INC. | $39.60 | 2025 | Nuvision Ice Catheter, Carto 3 |
| Scilex Pharmaceuticals INC. | $38.90 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $36.83 | 2025 | Zoryve |
| Globus Medical, INC. | $29.43 | 2025 | Senza |
| Aimmune Therapeutics, INC. | $28.36 | 2025 | Zenpep |
| Sanofi-Aventis U.S. LLC | $26.98 | 2025 | |
| Abbott Laboratories | $24.66 | 2025 | Freestyle Libre 3 |
| Biogen, INC. | $24.15 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Avanir Pharmaceuticals, INC. | $16.14 | 2021 | |
| Amarin Pharma, INC. | $15.80 | 2019 | |
| Eisai INC. | $14.69 | 2020 | |
| Hikma Pharmaceuticals USA | $12.99 | 2022 | |
| Endogastric Solutions, INC | $12.64 | 2022 | |
| Merck Sharp & Dohme LLC | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pierre Deltor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.